TFF Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
TFF Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2018 to Q3 2024.
  • TFF Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$3.54M, a 19.6% increase year-over-year.
  • TFF Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$18.5M, a 22.4% increase year-over-year.
  • TFF Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$21.2M, a 33.1% increase from 2022.
  • TFF Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$31.8M, a 2.36% decline from 2021.
  • TFF Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$31M, a 67.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$18.5M -$3.54M +$864K +19.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-20
Q2 2024 -$19.4M -$4.48M +$541K +10.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-20
Q1 2024 -$19.9M -$5.74M +$1.32M +18.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-20
Q4 2023 -$21.2M -$4.76M +$2.61M +35.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$23.9M -$4.41M +$2.87M +39.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-20
Q2 2023 -$26.7M -$5.02M +$3.73M +42.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-20
Q1 2023 -$30.4M -$7.05M +$1.32M +15.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-20
Q4 2022 -$31.8M -$7.37M +$2.68M +26.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$34.4M -$7.27M +$1.4M +16.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$35.9M -$8.75M -$4.09M -87.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$31.8M -$8.38M -$721K -9.43% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$31M -$10M -$4.15M -70.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$26.9M -$8.68M -$3.62M -71.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$23.3M -$4.66M -$839K -22% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$22.4M -$7.65M -$3.86M -102% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$18.6M -$5.9M -$1.23M -26.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 -$17.3M -$5.06M -$2.22M -78.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$15.1M -$3.82M -$1.63M -74.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$13.5M -$3.8M -$1.61M -74% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
Q4 2019 -$11.9M -$4.66M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-10
Q3 2019 -$2.84M -$2.25M -385% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$2.19M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$2.18M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q3 2018 -$585K Jul 1, 2018 Sep 30, 2018 10-Q 2019-12-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.